Latest Breaking News On - Prnewswire regulus therapeutics inc - Page 3 : comparemela.com

Regulus Therapeutics Announces Appointment of Preston S Klassen, M D to its Board of Directors

/PRNewswire/ Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines.

United statesSan diegoStelios papadopoulosPrestons klassenPreston klassenHead of researchPrnewswire regulus therapeutics incRnas the company or regulusArena pharmaceuticalsCompany board of directorsUniversity of nebraska medical centerHead of global development at orexigen therapeuticsRegulus therapeutics incHead of research developmentRegulus therapeuticsExecutive vice president

Regulus Therapeutics Strengthens Research & Development Leadership

/PRNewswire/ Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines.

San diegoUnited statesCurtis monnigPrestons klassenCurtisa monnigPreston klassenJay haganRegulus therapeutics incRnas the company or regulusIndiana universityUniversity of nebraska medical centerHead of research developmentCurrax pharmaceuticalsArena pharmaceuticalsPrnewswire regulus therapeutics incHead of global development at orexigen therapeutics

Regulus Therapeutics Announces $15 Million Private Placement of Equity

Regulus Therapeutics Announces $15 Million Private Placement of Equity
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesSan diegoExchange commissionRnas the company or regulusPrnewswire regulus therapeutics incRegulus therapeutics incEnterprise associatesHc wainwright coFederated hermes kaufmann fundsNew enterprise associatesCommon stockSecurities actPrivate securities litigation reform act

Regulus Therapeutics Announces Completion of Enrollment in First Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)

SAN DIEGO, April 12, 2023 /PRNewswire/ Regulus Therapeutics Inc. , a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs , today. | April 12, 2023

United statesSan diegoJay haganRegulus therapeutics incRnas the company or regulusPrnewswire regulus therapeutics incExchange commissionDominant polycystic kidney diseasePrivate securities litigation reform actRegulus therapeutics inc stock exchangePress releaseIcrornas rgls us75915k3095

Regulus Therapeutics Announces Completion of Enrollment in First Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Patients with Autosomal Dominant Polyc

Regulus Therapeutics Announces Completion of Enrollment in First Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Patients with Autosomal Dominant Polyc
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesSan diegoJay haganPrnewswire regulus therapeutics incRegulustherapeutics incRegulus therapeutics incExchange commissionRnas the company or regulusDominant polycystic kidney diseasePrivate securities litigation reform act